(OGN) Organon - Ratings and Ratios
Contraception, Fertility, Biosimilars, Cholesterol, Respiratory
OGN EPS (Earnings per Share)
OGN Revenue
Description: OGN Organon
Organon & Co is a global healthcare company that develops and delivers health solutions through a diverse portfolio of prescription therapies and medical devices. The companys product offerings span multiple therapeutic areas, including womens health, biosimilars, cardiovascular, respiratory, dermatology, bone health, and pain management. Its womens health portfolio is particularly notable, with brands such as Nexplanon and NuvaRing providing innovative contraceptive solutions. The companys biosimilars portfolio is also significant, with products like Brenzys and Renflexis offering more affordable alternatives to branded biologics.
From a business perspective, Organon & Co has a broad geographic reach, with products sold in over 100 countries worldwide. The company sells its products to a range of customers, including drug wholesalers and retailers, hospitals, clinics, government agencies, and health maintenance organizations. With a market capitalization of approximately $2.65 billion, Organon & Co is a mid-cap pharmaceutical company with a significant presence in the global healthcare market.
Some key performance indicators (KPIs) that can be used to evaluate Organon & Cos financial performance include revenue growth, gross margin, and operating cash flow. The companys return on equity (RoE) of 181.71% suggests that it is generating significant returns on shareholder equity. Additionally, the companys forward price-to-earnings (P/E) ratio of 5.03 suggests that it may be undervalued relative to its earnings growth potential. Other relevant KPIs could include the companys research and development (R&D) pipeline, product approval rates, and market share trends in key therapeutic areas.
Overall, Organon & Cos diverse product portfolio, broad geographic reach, and strong financial performance make it an attractive investment opportunity for investors seeking exposure to the global pharmaceutical market. However, a more detailed analysis of the companys financials, R&D pipeline, and competitive positioning would be necessary to fully evaluate its investment potential.
OGN Stock Overview
| Market Cap in USD | 2,449m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2021-06-02 |
OGN Stock Ratings
| Growth Rating | -84.8% |
| Fundamental | 61.6% |
| Dividend Rating | 49.7% |
| Return 12m vs S&P 500 | -56.5% |
| Analyst Rating | 3.0 of 5 |
OGN Dividends
| Dividend Yield 12m | 4.84% |
| Yield on Cost 5y | 2.20% |
| Annual Growth 5y | 18.92% |
| Payout Consistency | 98.0% |
| Payout Ratio | 15.8% |
OGN Growth Ratios
| Growth Correlation 3m | -8.3% |
| Growth Correlation 12m | -86% |
| Growth Correlation 5y | -87% |
| CAGR 5y | -23.93% |
| CAGR/Max DD 3y | -0.34 |
| CAGR/Mean DD 3y | -0.63 |
| Sharpe Ratio 12m | -0.57 |
| Alpha | 0.07 |
| Beta | 0.823 |
| Volatility | 40.99% |
| Current Volume | 3695k |
| Average Volume 20d | 3615.1k |
| Stop Loss | 9.9 (-4.4%) |
| Signal | 0.61 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (700.0m TTM) > 0 and > 6% of Revenue (6% = 376.9m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -4.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 29.01% (prev 27.64%; Δ 1.37pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 531.3m <= Net Income 700.0m (YES >=105%, WARN >=100%) |
| Net Debt (8.30b) to EBITDA (1.52b) ratio: 5.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (260.2m) change vs 12m ago 0.60% (target <= -2.0% for YES) |
| Gross Margin 56.26% (prev 58.59%; Δ -2.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.97% (prev 52.21%; Δ -3.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.30 (EBITDA TTM 1.52b / Interest Expense TTM 514.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.83
| (A) 0.13 = (Total Current Assets 4.62b - Total Current Liabilities 2.80b) / Total Assets 13.50b |
| (B) 0.09 = Retained Earnings (Balance) 1.16b / Total Assets 13.50b |
| (C) 0.09 = EBIT TTM 1.18b / Avg Total Assets 12.83b |
| (D) 0.05 = Book Value of Equity 594.0m / Total Liabilities 12.77b |
| Total Rating: 1.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.56
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 3.01% = 1.50 |
| 3. FCF Margin 5.15% = 1.29 |
| 4. Debt/Equity 12.14 = -2.50 |
| 5. Debt/Ebitda 5.86 = -2.50 |
| 6. ROIC - WACC 13.32% = 12.50 |
| 7. RoE 125.0% = 2.50 |
| 8. Rev. Trend 39.55% = 2.97 |
| 9. EPS Trend -23.98% = -1.20 |
What is the price of OGN shares?
Over the past week, the price has changed by -0.10%, over one month by +11.64%, over three months by +1.89% and over the past year by -48.34%.
Is Organon a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OGN is around 7.76 USD . This means that OGN is currently overvalued and has a potential downside of -25.1%.
Is OGN a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 3
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the OGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.2 | 27.1% |
| Analysts Target Price | 13.2 | 27.1% |
| ValueRay Target Price | 8.7 | -16% |
Last update: 2025-09-03 04:44
OGN Fundamental Data Overview
CCE Cash And Equivalents = 599.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 3.5019
P/E Forward = 5.0302
P/S = 0.3899
P/B = 3.3409
Beta = 0.565
Revenue TTM = 6.28b USD
EBIT TTM = 1.18b USD
EBITDA TTM = 1.52b USD
Long Term Debt = 8.78b USD (from longTermDebt, last quarter)
Short Term Debt = 115.0m USD (from shortTermDebt, last quarter)
Debt = 8.90b USD (Calculated: Short Term 115.0m + Long Term 8.78b)
Net Debt = 8.30b USD (from netDebt column, last quarter)
Enterprise Value = 10.75b USD (2.45b + Debt 8.90b - CCE 599.0m)
Interest Coverage Ratio = 2.30 (Ebit TTM 1.18b / Interest Expense TTM 514.0m)
FCF Yield = 3.01% (FCF TTM 323.2m / Enterprise Value 10.75b)
FCF Margin = 5.15% (FCF TTM 323.2m / Revenue TTM 6.28b)
Net Margin = 11.14% (Net Income TTM 700.0m / Revenue TTM 6.28b)
Gross Margin = 56.26% ((Revenue TTM 6.28b - Cost of Revenue TTM 2.75b) / Revenue TTM)
Tobins Q-Ratio = 18.09 (Enterprise Value 10.75b / Book Value Of Equity 594.0m)
Interest Expense / Debt = 1.48% (Interest Expense 132.0m / Debt 8.90b)
Taxrate = -7.06% (set to none) (-57.0m / 807.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.65 (Total Current Assets 4.62b / Total Current Liabilities 2.80b)
Debt / Equity = 12.14 (Debt 8.90b / last Quarter total Stockholder Equity 733.0m)
Debt / EBITDA = 5.86 (Net Debt 8.30b / EBITDA 1.52b)
Debt / FCF = 27.52 (Debt 8.90b / FCF TTM 323.2m)
Total Stockholder Equity = 560.0m (last 4 quarters mean)
RoA = 5.19% (Net Income 700.0m, Total Assets 13.50b )
RoE = 125.0% (Net Income TTM 700.0m / Total Stockholder Equity 560.0m)
RoCE = 12.66% (Ebit 1.18b / (Equity 560.0m + L.T.Debt 8.78b))
RoIC = 13.32% (Ebit 1.18b / (Assets 13.50b - Current Assets 4.62b))
WACC = unknown (E(2.45b)/V(11.34b) * Re(9.05%)) + (D(8.90b)/V(11.34b) * Rd(1.48%) * (1-Tc(none)))
Shares Correlation 3-Years: 93.94 | Cagr: 0.18%
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.78% ; FCFE base≈508.7m ; Y1≈583.0m ; Y5≈812.1m
Fair Price DCF = 44.91 (DCF Value 11.68b / Shares Outstanding 260.0m; 5y FCF grow 17.06% → 3.0% )
EPS Correlation: -23.98 | EPS CAGR: -9.60% | SUE: 0.39 | # QB: False
Revenue Correlation: 39.55 | Revenue CAGR: 1.33%
Additional Sources for OGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle